News | Radiation Therapy | October 03, 2017

ASTRO Awards Early-Career Research Grants to Physician-Scientists

Radiation oncology society announces $275,000 in grants to four researchers

ASTRO Awards Early-Career Research Grants to Physician-Scientists

October 3, 2017 — The American Society for Radiation Oncology (ASTRO) awarded $275,000 in research awards to four early-career scientists as part of the Society’s efforts to retain and foster the intellectual research talent currently entering the field of radiation oncology. For 2017, the Research Grants committee selected one Junior Faculty Award and three Resident Seed Grant recipients. All winners were recognized at ASTRO’s 59th Annual Meeting, taking place Sept. 24-27 in San Diego.

“ASTRO may not conduct its own scientific research — but we aim to create an environment where researchers are able to succeed. These grants recognize the innovative work being done by those in our field, and they also identify and encourage early-career researchers,” said ASTRO Chair David C. Beyer, M.D., FASTRO. “By supporting these researchers, our specialty will benefit from their discoveries, which, in turn, will eventually lead to better outcomes for our patients — the ultimate goal we physicians strive for, every day.”

The ASTRO Junior Faculty Career Research Training Award (JFA) gives early-career physicians and researchers the opportunity to develop careers and focus on research relevant to radiation oncology, biology or physics. Recipients must be board-eligible physicians, physicists in radiation oncology or radiobiologists within the first three years of their junior faculty appointment. One junior faculty member was selected for this award, which provides $100,000 annually for two years.

  The 2017 JFA grant recipient is Erina Vlashi, Ph.D., from the University of California Los Angeles (UCLA). Vlashi is interested in how ionizing radiation (IR) induces the reprogramming of breast cancer cells into breast-cancer-initiating or stem cells that can lead to increased tumor growth and treatment resistance. Understanding the steps in how radiation alters the metabolic state of breast tumor cells can provide key insights into how these cells will respond to subsequent IR exposure.

The ASTRO Resident/Fellows in Radiation Oncology Research Seed Award supports residents or fellows who are planning a career in basic science or clinical research in radiation oncology. Three researchers were selected for this award, which provides $25,000 per recipient for one year. The three 2017 Resident/Fellows in Radiation Oncology Research Seed Award recipients are:

  • Devarati Mitra, M.D., Ph.D., from the Dana-Farber Cancer Institute, Boston. Mitra will investigate how administration of hypofractionated radiation modulates the immune response in head and neck carcinoma. He will explore if such modulation can increase the efficacy of immune checkpoint inhibitors when combined with radiation;
  • Shushan Rana, M.D., from the Oregon Health & Science University, Portland, Ore. Rana will investigate how microRNA, specifically miR-15a, affects endothelial radiosensitivity through regulation of acid sphingomyelinase ceramide-induced apoptosis, a pathway which is preferentially induced at higher doses of radiation. He hopes to ultimately prevent the development of immune cell anergy and/or exhaustion to improve tumor responses to anti-tumor treatment; and
  • Ye Yuan, M.D., from UCLA. Yuan’s interest is in how tumors evade the immune system through upregulation of PD-L1 and PD-L2 expression. Mediators that inhibit gene expression including micro-RNA molecules can be activated by radiation treatment. How radiation activates miR-34 that subsequently binds to and downregulates PD-L1 and PD-L2 expression still remains unclear and may be an effective way to stimulate the immune response to kill tumor cells.

All awardees must submit a report to ASTRO at the midterm and the conclusion of their research, and they are strongly encouraged to submit their study as an abstract to a subsequent ASTRO Annual Meeting. The grant winners are selected by ASTRO’s Research Grants Evaluation Committee within the Science Council and approved by the ASTRO Board of Directors.

For more information: www.astro.org

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Treatment Planning | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing  synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of  the anatomy.

A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of the anatomy.

Feature | Radiation Oncology | May 29, 2019 | By Jeff Zagoudis
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin